K. Mahoney

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

A. Pestronk, D. Schoenfeld, P. Andres, 2013, The Lancet Neurology.

Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial

J. Lou, J. Glass, M. Cudkowicz, 2014, The Lancet.

Hypercaloric enteral nutrition in Amyotrophic Lateral Sclerosis: a randomized double-blind placebo-controlled trial

J. Lou, J. Glass, H. Mitsumoto, 2014 .

Title Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis : a randomised , double-blind , placebo-controlled phase 2 trial

J. Lou, J. Glass, M. Cudkowicz, 2014 .

Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis

A. Pestronk, D. Schoenfeld, M. Cudkowicz, 2020, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis

M. Cudkowicz, J. Cedarbaum, J. Shefner, 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.

B. Dobkin, K. Marder, J. Long, 2020, JAMA neurology.